UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma

Frontiers in oncology, 2024-08, Vol.14, p.1455464

2024

Volltextzugriff (PDF)

Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study)

Life (Basel, Switzerland), 2024-03, Vol.14 (3), p.384

2024

Volltextzugriff (PDF)

Practical Considerations in Managing Relapsed Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2017-02, Vol.17 (2), p.69-77

2017

Volltextzugriff (PDF)

Fragile Warriors: Navigating the Delicate Dance of Frailty and CAR-T cell Therapy for Relapsed/Refractory Multiple Myeloma

Transplantation and cellular therapy, 2024-03, Vol.30 (3), p.253-254

2024

Volltextzugriff (PDF)

Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Blood, 2023-11, Vol.142 (Supplement 1), p.3380-3380

2023

Volltextzugriff (PDF)

Daratumumab, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma (RRMM): A comparison with contemporary clinical trials

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e20011-e20011

2021

Volltextzugriff (PDF)

Outcomes for transplant-eligible, newly diagnosed Black patients (Pts) with multiple myeloma (MM): The Levine Cancer Institute (LCI) experience

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8053-8053

2022

Volltextzugriff (PDF)

Phase II Trial of Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) after One Prior Line of Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.2739-2739

2021

Volltextzugriff (PDF)

Central Memory T-Cell Differentiation Correlates with Depth of Response in Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone (Elo-KRd)

Blood, 2021-11, Vol.138 (Supplement 1), p.1585-1585

2021

Volltextzugriff (PDF)

Genetic polymorphisms associated with clostridium difficile infection in multiple myeloma patients undergoing autologous stem cell transplantation

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8522-8522

2020

Volltextzugriff (PDF)

OA-57 Results of a Phase 1 Clinical Trial of Belantamab Mafadotin (BelMaf) Combined With Carfilzomib, Lenalidomide, and Dexamethasone (KRd) for Multiple Myeloma (MM) After One Prior Line of Therapy (LOT)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S36-S36

2024

Volltextzugriff (PDF)

P-078 Prompt and Profound Responses with Talquetamab in Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma – Another Bridging Therapy

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S86-S87

2024

Volltextzugriff (PDF)

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

Blood, 2020-11, Vol.136 (Supplement 1), p.38-39

2020

Volltextzugriff (PDF)

Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma

Life (Basel, Switzerland), 2024-03, Vol.14 (3)

2024

Volltextzugriff (PDF)

P-242: Efficacy of selinexor in relapsed/refractory multiple myeloma (RRMM) patients with del17p and other high-risk abnormalities: a retrospective single-center study

Clinical lymphoma, myeloma and leukemia, 2022-08, Vol.22, p.S168-S169

2022

Volltextzugriff (PDF)

P-173: Prognostic utility of the evolving biomarkerbased progression model (e-model) for smoldering multiple myeloma (SMM) in a diverse population

Clinical lymphoma, myeloma and leukemia, 2022-08, Vol.22, p.S130

2022

Volltextzugriff (PDF)

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

Blood, 2018-11, Vol.132 (Supplement 1), p.2255-2255

2018

Volltextzugriff (PDF)

Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma

British journal of haematology, 2019-07, Vol.186 (1), p.140-144

2019

Volltextzugriff (PDF)

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Blood, 2019-11, Vol.134 (Supplement_1), p.5570-5570

2019

Volltextzugriff (PDF)

P-079 Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S87-S88

2024

Volltextzugriff (PDF)

Phase II Trial Daily Pulse Interleukin-2 Therapy with Famotidine during Marrow and Lymphocyte Recovery in Acute Myeloid Leukemia: LJCC 0605

Blood, 2015-12, Vol.126 (23), p.3783-3783

2015

Volltextzugriff (PDF)

A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse

Clinical lymphoma, myeloma and leukemia, 2023-07, Vol.23 (7), p.535-544.e1

2023

Volltextzugriff (PDF)

Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol

Clinical lymphoma, myeloma and leukemia, 2020-08, Vol.20 (8), p.526-532.e1

2020

Volltextzugriff (PDF)

Peripheral Cellular Immunome Reveals Heterogeneity Spanning Myeloma Spectrum Diseases

Blood, 2017-12, Vol.130, p.3054-3054

2017

Volltextzugriff (PDF)

Validation of Dynamic Biomarker-Based Risk Progression Model for Smoldering Multiple Myeloma

Blood, 2017-12, Vol.130, p.1779-1779

2017

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Englisch
(60)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma

Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study)

Practical Considerations in Managing Relapsed Multiple Myeloma

Fragile Warriors: Navigating the Delicate Dance of Frailty and CAR-T cell Therapy for Relapsed/Refractory Multiple Myeloma

Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Daratumumab, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma (RRMM): A comparison with contemporary clinical trials

Outcomes for transplant-eligible, newly diagnosed Black patients (Pts) with multiple myeloma (MM): The Levine Cancer Institute (LCI) experience

Phase II Trial of Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) after One Prior Line of Therapy

Central Memory T-Cell Differentiation Correlates with Depth of Response in Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone (Elo-KRd)

Genetic polymorphisms associated with clostridium difficile infection in multiple myeloma patients undergoing autologous stem cell transplantation

OA-57 Results of a Phase 1 Clinical Trial of Belantamab Mafadotin (BelMaf) Combined With Carfilzomib, Lenalidomide, and Dexamethasone (KRd) for Multiple Myeloma (MM) After One Prior Line of Therapy (LOT)

P-078 Prompt and Profound Responses with Talquetamab in Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma – Another Bridging Therapy

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma

P-242: Efficacy of selinexor in relapsed/refractory multiple myeloma (RRMM) patients with del17p and other high-risk abnormalities: a retrospective single-center study

P-173: Prognostic utility of the evolving biomarkerbased progression model (e-model) for smoldering multiple myeloma (SMM) in a diverse population

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

P-079 Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Phase II Trial Daily Pulse Interleukin-2 Therapy with Famotidine during Marrow and Lymphocyte Recovery in Acute Myeloid Leukemia: LJCC 0605

A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse

Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol

Peripheral Cellular Immunome Reveals Heterogeneity Spanning Myeloma Spectrum Diseases

Validation of Dynamic Biomarker-Based Risk Progression Model for Smoldering Multiple Myeloma

Suchergebnisse filtern